Congressman Josh Brecheen, who represents Oklahoma’s 2nd district in the U.S. Congress, recently posted a series of statements on his official X (formerly Twitter) account criticizing federal decisions and highlighting ongoing political issues.
On October 3, 2025, Brecheen expressed strong opposition to the Food and Drug Administration’s approval of a generic version of mifepristone. In his post, he stated: “The FDA’s recent approval of the generic version of mifepristone is completely unacceptable. Grateful to @RepMarkHarrisNC for leading this letter to @SecKennedy respectfully demanding accountability from those responsible for this horrible decision.” The same day, Brecheen shared another post linking to additional information without further comment: “https://t.co/5lMHyIdBjR”.
Continuing his activity on social media, Brecheen commented on the ongoing government funding impasse by posting on October 4, 2025: “#SchumerShutdown Day 4 https://t.co/RB8V7VcZjx”.
Josh Brecheen has served in Congress since 2023 after replacing Markwayne Mullin. He previously held office in the Oklahoma Senate from 2010 to 2018 and was born in Ada, Oklahoma in 1979. Brecheen resides in Coalgate and holds a bachelor’s degree from Southeastern Oklahoma State University.
